Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACDC adjuvant trial of autologous tumor lysate-pulsed dendritic cell vaccination in resected stage III/IV melanoma
2014-005123-27Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Dec 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of autologous tumor lysate-pulsed dendritic cells and aldesleukin in melanoma (2 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Relapse-free survival. Started Dec 2017; status: terminated.
02
Drugs
autologous tumor lysate-pulsed dendritic cellsaldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on 2014-005123-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005123-27.